Treatment Development & Evaluation Core

治疗开发和评估核心项目摘要 数字疗法在克服获得高质量的实质性挑战方面大有可为， 对物质使用障碍(SODS)和精神或身体共生的经验性治疗 健康状况(CODS)。数字创新可以增强现有干预的效力，扩展其 覆盖范围，降低成本。使用智能手机进行行为和生理监测的数字生物标记物 可穿戴传感器(即被动感知)可以提高评估过程的特异性，进而可以 提供个性化目标，以优化干预措施。支持数字治疗学的发展是 至关重要，因为大多数肥皂水患者不接受肥皂水治疗，而接受治疗的人只有一个 少数治疗是以证据为基础的。近9年来，治疗的发展与评价 (TDE)Core支持加强和加快对一系列技术的研究，这些技术可以 改善医疗服务提供情况。我们的核心子公司的研究提升了可行性、可接受性、可用性、 创新的数字健康评估工具和干预措施对多种类型的肥胖症的疗效 不同的人群。这些项目也提高了我们对发展和维持的理解 肥皂水的影响因素和变化机制。在拟议的续期内，TDE核心将继续 提高跨学科专家队伍中研究项目的质量、效率和影响力。这个 CORE将继续在CTBH附属公司和更大的公司之间共享资源，并扩大活动 科学界和临床界(目标1)，并提供支持加速和 科学的积累将增强我们对可以优化数字治疗的因素的理解 肥皂和鳕鱼(目标2)。这些努力将包括5个新的CTBH优先事项(例如，扩展数字 治疗学，数字测量，以告知个性化即时适应干预(JITAI)， 整合CODS和跨诊断机制和干预措施，数字健康伦理，并纳入 代表不足的少数群体)。例如，我们将加强我们的咨询服务，以准备 通过扩大在优先领域拥有专业知识的顾问阵容来竞争赠款申请，并将 通过开发和举办网络研讨会，细化教育活动的重点，提高教育活动的强度， 教程和跨核心讲习班，提供关于高优先研究目标的深入培训。《核心》 还将与正在进行或正在进行的数字健康项目的附属公司接洽，以包括以下额外的研究目标 解决我们的新优先事项。例如，添加与扩展、变化机制、 或跨诊断过程；包括被动传感评估，以收集数字表型数据， 与药物使用或复发有关；并评估SUD项目中的COD，以评估它们如何缓解 干预效果以及跨诊断干预如何影响结果。这些努力将加快 针对不同人群的肥胖症和相关疾病的数字治疗科学的最新进展。

TREATMENT DEVELOPMENT AND EVALUATION CORE PROJECT SUMMARY Digital therapeutics hold great promise in overcoming the substantial challenges in accessing high quality, empirically supported treatments for substance use disorders (SUDs) and co-occurring mental or physical health conditions (CODs). Digital innovations can enhance the potency of existing interventions, extend their reach, and reduce costs. Digital biomarkers from behavioral and physiological monitoring using smartphones and wearable sensors (i.e., passive sensing) can improve specificity of assessment processes that in turn can provide personalized targets to optimize interventions. Supporting the development of digital therapeutics is vital, as most persons with SUDs do not receive SUD treatment, and of those who do receive treatment, only a minority of treatments are evidence-based. Over the past 9 years, the Treatment Development and Evaluation (TDE) Core has supported activities that enhance and expedite research on an array of technologies that can improve treatment delivery. Our Core affiliates’ research has advanced the feasibility, acceptability, usability, and efficacy of innovative digital health assessment tools and interventions for multiple types of SUDs among diverse populations. These projects have also improved our understanding of developmental, and maintaining factors, and mechanisms of change for SUDs. In the proposed renewal period, the TDE Core will continue to enhance the quality, efficiency, and impact of research projects among an interdisciplinary expert faculty. The Core will continue with, and expand activities for, sharing resources among CTBH affiliates and the greater scientific and clinical communities (Aim 1), and provide mechanisms to support the acceleration and accumulation of science that will enhance our understanding of factors that can optimize digital therapeutics for SUDs and CODs (Aim 2). These efforts will embrace the 5 new CTBH priorities (e.g., scaling of digital therapeutics, digital measurement to inform personalized just-in-time adaptive interventions (JITAIs), integration of CODs and transdiagnostic mechanisms and interventions, digital health ethics, and inclusion of underrepresented minority populations). For example, we will enhance our consultation services for preparing competitive grant applications by expanding the array of Advisors with expertise in the priority areas, and will refine the focus and enhance the intensity of our educational activities by developing and delivering webinars, tutorials, and cross-Core workshops that provide in-depth training on high priority research targets. The Core will also engage affiliates with active or pending digital health projects to include additional research aims that address our new priorities. e.g., add common metrics of outcomes related to scaling, mechanisms of change, or transdiagnostic processes; include passive sensing assessment to collect digital phenotyping data that may relate to substance use or relapse; and assess CODs in SUD projects to evaluate how they moderate intervention effects and how transdiagnostic interventions impact outcomes. These efforts will accelerate the state-of-the science of digital therapeutics for SUDs and related conditions across diverse populations.